NeuroSense Therapeutics up as FDA permits patient enrolment in ALS drug study

Neurosense Therapeutics

15/11/2022 14:14

** NeuroSense Therapeutics Ltd's shares  NRSN.O  rise 16.8%
to $1.84 premarket
    ** U.S. FDA approves NRSN's application to enroll patients
in the U.S. for its mid-stage study of experimental drug to
treat patients with amyotrophic lateral sclerosis (ALS)
 urn:newsml:reuters.com:*:nPn1H1LYQa
    ** In the ongoing mid-stage study, drug developer is
currently enrolling patients in Israel and expected to open
clinical sites in Europe in coming weeks 
    ** ALS is a rare neurological disease, which is caused by
gradual deterioration and death of nerve cells leading to
paralysis or death - NIH
    ** Up to Monday's close, stock lost ~36% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))